Cannabioids as a New Intervention for Amphetamine Dependence

Phase 2

Withdrawn

• Conditions: Amphetamine Addiction
• Interventions: Drug: drug administration

• Registration Number: NCT02952196
• Lead Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Brief Summary

Addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Addiction involves a number of neurotransmission systems, including the endocannabinoid system (ECBS). It has been demonstarted that cannabidioids can have physiological, anxiolytic and neuroprotective properties. It has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly cannabinoids have been shown to be potentially helpful in treating addiction, due to their effects on various neuronal circuits involved in this disorder.

The investigators overall hypothesis is that cannabinoids are an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-10-27
• Study Start: 2016-11
• Study First Submitted QC: 2016-11-01
• Study First Posted: 2016-11-02
• Primary Completion: 2017-12
• Study Completion: 2017-12
• Status Verified: 2019-01
• Last Update Submitted: 2020-10-21
• Last Update Posted: 2020-10-23

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Current DSM-V criteria for amphetamine use disorder
• Ability to give valid, informed consent

Exclusion Criteria

• Severe and/or unstable hepatic, neurologic (including diagnosis of seizures), cardiac (including arrhythmias) or renal disease, or any other severe or unstable medical condition that precludes safe participation in the study according to the study physician.
• Severe psychiatric condition (history of schizophrenia, schizoaffective disorder or bipolar disorder; current acute psychosis, mania or severe suicidality
• Any serious medical condition or psychiatric illness that precludes the subject from signing the informed consent form

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
placebo	drug administration	-
cannabinoid dose 1	drug administration	-
cannabinoid dose 2	drug administration	-

Primary Outcome Measures

Name	Time	Method
assessing amphetamine craving	everyday during the study (that will last 3 days for each participants)	using questionnaire to assess craving and taking vital signs

Trial Locations

Locations (1)

Centre hospitalier de l'Université de Montréal; 🇨🇦 Montreal, Quebec, Canada